Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial

Abstract

BackgroundThe prevalence of type 2 diabetes (T2D) is increasing worldwide and creating a significant burden on health systems, highlighting the need for the development of innovative therapeutic approaches to overcome immune dysfunction, which is likely a key factor in the development of insulin resistance in T2D. It suggests that immune modulation may be a useful tool in treating the disease.MethodsIn an open-label, phase 1/phase 2 study, patients (N = 36) with long-standing T2D were divided into three groups (Group A, oral medications, n = 18; Group B, oral medications + insulin injections, n = 11; Group C having impaired β-cell function with oral medications + insulin injections, n = 7). All patients received one treatment with the Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separates mononuclear cells from the whole blood, briefly co-cultures them with adherent cord blood-derived multipotent stem cells (CB-SCs), and returns the educated autologous cells to the patient’s circulation.ResultsClinical findings indicate that T2D patients achieve improved metabolic control and reduced inflammation markers after receiving Stem Cell Educator therapy. Median glycated hemoglobin (HbA1C) in Group A and B was significantly reduced from 8.61% ± 1.12 at baseline to 7.25% ± 0.58 at 12 weeks (P = 2.62E-06), and 7.33% ± 1.02 at one year post-treatment (P = 0.0002). Homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) demonstrated that insulin sensitivity was improved post-treatment. Notably, the islet beta-cell function in Group C subjects was markedly recovered, as demonstrated by the restoration of C-peptide levels. Mechanistic studies revealed that Stem Cell Educator therapy reverses immune dysfunctions through immune modulation on monocytes and balancing Th1/Th2/Th3 cytokine production.ConclusionsClinical data from the current phase 1/phase 2 study demonstrate that Stem Cell Educator therapy is a safe approach that produces lasting improvement in metabolic control for individuals with moderate or severe T2D who receive a single treatment. In addition, this approach does not appear to have the safety and ethical concerns associated with conventional stem cell-based approaches.Trial registrationClinicalTrials.gov number, NCT01415726

Platelet-Derived Mitochondria Display Embryonic Stem Cell Markers and Improve Pancreatic Islet β-cell Function in Humans

“…Based on their unique properties in immune modulation , we developed a new technology, called Stem Cell Educator (SCE) therapy, by using CB‐SCs in a closed‐loop system that circulates a patient's blood through a blood cell separator, briefly co‐cultures the patient's lymphocytes with adherent CB‐SCs in vitro, and returns the “educated” lymphocytes (but not the CB‐SCs) to the patient's circulation . A single treatment with SCE therapy provides lasting reversal of autoimmunity, leading to the regeneration of islet β cells and improvement of metabolic control in individuals with longstanding T1D and T2D . Specifically, a recent phase I/II study demonstrated the safety and feasibility of SCE therapy in the treatment of alopecia areata (AA) , one of the most common T cell‐mediated autoimmune diseases.…”

Associations of pancreatic β-cell function and insulin resistance with microalbuminuria in type 2 diabetes

“…As far as we know, this is the first study to evaluate fasting C-peptide-derived indices of pancreatic b-cell function and insulin sensitivity in relation to microvascular complications in T2DM. We used fasting plasma C-peptide instead of fasting insulin, because C-peptide is a by-product of insulin synthesis and is released at equal levels, while the accuracy of HOMA-B and HOMA-IR calculated using fasting insulin was limited, owing to the external insulin injections and other treatments in T2DM patients [7]. We simultaneously combined pancreatic b-cell function with insulin resistance to evaluate both factors' influence on microalbuminuria in T2DM, in contrast with previous studies which assessed the association of microalbuminuria with a single factor, e.g., pancreatic b-cell function or insulin resistance.…”

Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood–Derived Cells

“…Indeed, a phase I/II clinical trial showed that UCB-derived multipotent progenitors that coexpress CD45 can educate autologous peripheral blood mononuclear cells in a closed loop system and can attenuate immunological regulators in type 2 diabetes. Insulin sensitivity was improved after treatment with some recovery of islet b cell function, perhaps through balancing of Th1/Th2/Th3 cytokine production [93].…”